All News
STAT+: The shrewd startup founder who led DOGE’s cost-cutting at HHS
The relentless drumbeat of cuts to U.S. government research and disease prevention have devastated tens of thousands of affected workers and academics.
Read MoreOpinion: I worked at 23andMe during its collapse. Here’s what the next consumer-genomics giant needs to understand
“In trying to lead before the system could follow, 23andMe outpaced the very guardrails that might have legitimized it”: A former 23andMe employee offers three pieces of advice to the…
Read MoreOpinion: Medicine warns doctors not to get too close. I’m glad mine did anyway
Imagine a medical system that embraces doctors’ emotional investment in patients as a strength rather than a liability.
Read MoreSTAT+: Sanofi to buy Blueprint Medicines in deal worth more than $9 billion
Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline
Read MorePersonalised nutrition: Bridging ancient wisdom and modern science for cardiometabolic health
Dr Rohit Sane, CEO & Managing Director, Madhavbaug Clinics & Hospitals explains how ayurveda’s Prakruti framework, validated by modern genetic research, offers a lens through which person
Read MoreLondon mayor reverses TfL ban on ads calling for abortion decriminalisation
Sadiq Khan seeking ‘urgent review’ of decision to ban adverts from British Pregnancy Advisory ServiceThe mayor of London, Sadiq Khan, has stepped in to reverse a ban on adverts on the London trans
Read MoreMonday briefing: What Nigel Farage’s new obsession with nativism could mean for the UK
In today’s newsletter: Reform’s latest policy shift echoes strategies seen in Europe’s far right. Will this approach gain traction in the UK?Good morning.
Read MoreSpending on agency staff across NHS England drops by almost £1bn
Exclusive: Cost-saving for 2024-25 follows pledge by Wes Streeting to cut the amount going to agencies by 30%Spending on agency staff across NHS England dropped by almost £1bn in the last financial y
Read MoreSTAT+: At ASCO Day 3, AstraZeneca dominates, Takeda reveals experimental drug data, Eli Lilly serves salad
Let's talk about what happened today at ASCO, the world's biggest cancer meeting.
Read MoreAlternative Endpoints in Phase III Trials Don't Always Mean Boosts to OS, QOL
(MedPage Today) -- CHICAGO -- Late-phase trials that showed superiority for an experimental intervention on a surrogate endpoint did not necessarily lead to improvements in overall survival (OS) or
Read More